MaxiaVax

Maxi-VAX is a Swiss clinical-stage biotechnology company specializing in the development of personalized cancer immunotherapies. The company's lead product candidate, MVX-ON1, utilizes a proprietary macroencapsulation technology to deliver a potent immune-stimulating adjuvant, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), in close proximity to the patient's own irradiated tumor cells. This approach is designed to trigger a systemic, tumor-specific immune response to combat various types of solid tumors by overcoming local immune suppression. Maxi-VAX is currently advancing clinical programs in indications such as glioblastoma and chordoma, aiming to provide solutions for patients with limited treatment options. The company's unique delivery system ensures a continuous and controlled release of the adjuvant, enhancing the efficacy of the personalized vaccine.